Product Description
Mangafodipir is an MRI (magnetic resonance imaging) contrast agent (also known as paramagnetic agents). MRI agents are used to help provide a clear picture during MRI. MRI is a special kind of diagnostic procedure. It uses magnets and computers to create images or "pictures" of certain areas inside the body (Sourced from: https://www.mayoclinic.org/drugs-supplements/mangafodipir-intravenous-route/description/drg-20067273)
Mechanisms of Action: Contrast Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | European Medicines Agency | Germany | Greece | Hungary | Ireland | Italy | New Zealand | Portugal | Saudi Arabia | Slovenia | Sweden | Taiwan | Turkey | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|